<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392429</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2015-00328</org_study_id>
    <secondary_id>NCI-2015-00328</secondary_id>
    <secondary_id>EAI141</secondary_id>
    <secondary_id>EAI141</secondary_id>
    <secondary_id>EAI141</secondary_id>
    <secondary_id>U10CA180820</secondary_id>
    <secondary_id>U10CA180827</secondary_id>
    <nct_id>NCT02392429</nct_id>
  </id_info>
  <brief_title>FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
  <official_title>Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies fluorothymidine F 18 (FLT) positron emission tomography
      (PET)/computed tomography (CT) in measuring response in patients with previously untreated
      acute myeloid leukemia. FLT is a radioactive substance that may &quot;light up&quot; where cancer is in
      the body. FLT is injected into the blood and builds up in cells that are dividing, including
      cancer cells. Diagnostic procedures, such as PET/CT, may help measure a patient's response to
      earlier treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the negative predictive value (NPV) of post-treatment FLT PET/CT imaging for
      complete remission (CR) in patients receiving induction chemotherapy for acute myeloid
      leukemia (AML).

      SECONDARY OBJECTIVES:

      I. To evaluate the positive predictive value (PPV) of post-treatment FLT PET/CT imaging for
      complete remission.

      II. To estimate the sensitivity and specificity of FLT PET/CT at complete remission
      detection.

      III. To evaluate pre-treatment FLT PET/CT activity as a predictor of complete remission.

      IV. To evaluate the change between pre-treatment and post-treatment FLT PET/CT activity as a
      predictor of complete remission.

      V. To correlate post-treatment FLT PET/CT imaging parameters with day 28 bone marrow
      aspirate/biopsy and minimal residual disease assessment by flow cytometry.

      VI. To correlate FLT PET/CT imaging parameters (maximum FLT uptake across the total bone
      marrow compartment [SUVmax], mean FLT uptake across the total bone marrow compartment
      [SUVmean], heterogeneity) with biologic correlates (minimal residual disease [MRD]
      assessment).

      OUTLINE:

      Patients receive anthracycline intravenously (IV) on days 1-3 and cytarabine IV on days 1-7
      for up to 2 courses. Patients then undergo FLT PET/CT within 3 days before or after the nadir
      bone marrow biopsy (between days 10-17 after initiation of first induction cycle and prior to
      reinduction). Patients may undergo an optional FLT PET/CT prior to induction chemotherapy if
      it does not interfere with commencement of treatment.

      After completion of study, patients are followed up at day 28-35.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2015</start_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative predictive value of post-treatment FLT PET/CT imaging for CR in comparison with blast counts from bone marrow biopsy (BMBX)</measure>
    <time_frame>Up to day 35</time_frame>
    <description>Three imaging parameters (SUVmean, SUVmax, heterogeneity of FLT uptake [SUVhetero]) will be measured from an FLT PET/CT scan and SUVmax will be the primary endpoint. The binomial proportion of PPV and the corresponding Exact confidence intervals will be calculated. In addition, the calculated NPV will be tested against the null hypothesis to see if it's significantly larger than 0.64 (NPV of day-14 BMBX in CR prediction).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PPV of post-treatment FLT PET/CT imaging for complete remission</measure>
    <time_frame>Up to day 35</time_frame>
    <description>The binomial proportion of PPV and the corresponding Exact confidence intervals will be calculated. In addition, the calculated PPV will be tested to see if it's significantly larger than 0.79 (PPV of day-14 BMBX in CR prediction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of FLT PET/CT for complete remission detection</measure>
    <time_frame>Up to day 35</time_frame>
    <description>The binomial proportions and the corresponding Exact confidence intervals will be calculated for sensitivity estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of FLT PET/CT for complete remission detection</measure>
    <time_frame>Up to day 35</time_frame>
    <description>The binomial proportions and the corresponding Exact confidence intervals will be calculated for specificity estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment FLT PET/CT activity as a predictor of complete remission</measure>
    <time_frame>Baseline</time_frame>
    <description>The receiver operating characteristic (ROC) approach will be used to test the continue measurement of this variable in predicting CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between pre-treatment and post-treatment FLT PET/CT activity as a predictor of complete remission</measure>
    <time_frame>Baseline to up to day 35</time_frame>
    <description>The ROC approach will be used to test the continue measurement of this variable in predicting CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologic correlates of AML (MRD assessment)</measure>
    <time_frame>At day 14</time_frame>
    <description>Correlation of FLT PET/CT imaging parameters (SUVmax, SUVmean, SUVhetero) with biologic correlates will be studied and regression analysis will be used to assess this aim.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Diagnostic (anthracycline, cytarabine, FLT PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive anthracycline IV on days 1-3 and cytarabine IV on days 1-7 for up to 2 courses. Patients then undergo FLT PET/CT within 3 days before or after the nadir bone marrow biopsy (between days 10-17 after initiation of first induction cycle and prior to reinduction). Patients may undergo an optional FLT PET/CT prior to induction chemotherapy if it does not interfere with commencement of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Given anthracycline IV</description>
    <arm_group_label>Diagnostic (anthracycline, cytarabine, FLT PET/CT)</arm_group_label>
    <other_name>Chemo</other_name>
    <other_name>Chemotherapy (NOS)</other_name>
    <other_name>Chemotherapy, Cancer, General</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo FLT PET/CT</description>
    <arm_group_label>Diagnostic (anthracycline, cytarabine, FLT PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (anthracycline, cytarabine, FLT PET/CT)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluorothymidine F-18</intervention_name>
    <description>Undergo FLT PET/CT</description>
    <arm_group_label>Diagnostic (anthracycline, cytarabine, FLT PET/CT)</arm_group_label>
    <other_name>18F-FLT</other_name>
    <other_name>3'-Deoxy-3'-(18F) Fluorothymidine</other_name>
    <other_name>3'-deoxy-3'-[18F]fluorothymidine</other_name>
    <other_name>ALOVUDINE F-18</other_name>
    <other_name>fluorothymidine F 18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (anthracycline, cytarabine, FLT PET/CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo FLT PET/CT</description>
    <arm_group_label>Diagnostic (anthracycline, cytarabine, FLT PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have previously untreated AML and be candidates for intensive induction
             chemotherapy; patients are allowed to have had prior hydroxyurea

          -  Patients must not have acute promyelocytic leukemia (APL) and must not have evidence
             of t(15;17)(q22;q21)

          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             0-3 (restricted to ECOG performance status [PS] 0-2 if age &gt; 70 years)

          -  Patients must have left ventricular ejection fraction (LVEF) &gt; 45% or within
             institutional normal limits

          -  Patients must be able to lie still for a 1.5 hour PET scan

          -  Patient must NOT have a history of allergic reaction attributable to compounds of
             similar chemical or biologic composition to 18F-fluorothymidine

          -  Patient must NOT weigh more than the maximum weight limit for the PET/CT table for the
             scanner(s) to be used at each center

          -  The patient is participating in the trial at an institution which has agreed to
             perform the imaging research studies, completed the ECOG-American College of Radiology
             Imaging Network (ACRIN) defined scanner qualification procedures and received
             ECOG-ACRIN approval as outlined

          -  Women must not be pregnant or breast-feeding; all females of childbearing potential
             must have a blood test or urine study within 2 weeks prior to registration to rule out
             pregnancy; a female of childbearing potential is any woman, regardless of sexual
             orientation or whether they have undergone tubal ligation, who meets the following
             criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not
             been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses
             at any time in the preceding 24 consecutive months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Jeraj</last_name>
    <role>Principal Investigator</role>
    <affiliation>ECOG-ACRIN Cancer Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan E. McConathy</last_name>
      <phone>205-934-0220</phone>
      <email>tmyrick@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan E. McConathy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kebede H. Begna</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Kebede H. Begna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry A. Siegel</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Barry A. Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lale Kostakoglu</last_name>
      <phone>212-824-7309</phone>
      <email>CCTO@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Lale Kostakoglu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew C. Foster</last_name>
      <phone>877-668-0683</phone>
      <email>cancerclinicaltrials@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew C. Foster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer L. Holter-Chakrabarty</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer L. Holter-Chakrabarty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David A. Mankoff</last_name>
      <phone>800-474-9892</phone>
    </contact>
    <investigator>
      <last_name>David A. Mankoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia L. Kropf</last_name>
      <phone>215-728-4790</phone>
    </contact>
    <investigator>
      <last_name>Patricia L. Kropf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen A. Strickland</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Stephen A. Strickland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor J. Kovacsovics</last_name>
      <phone>801-581-4477</phone>
      <email>clinical.trials@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Tibor J. Kovacsovics</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan J. Mattison</last_name>
      <phone>800-622-8922</phone>
    </contact>
    <investigator>
      <last_name>Ryan J. Mattison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
    <mesh_term>Alovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

